Dr Reddy's Laboratories (DRL) has initiated voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market, following 'Failed Dissolution Specifications'. A total of 60 bottles of 2952 units are recalled on the direction of US Food and Drug Administration (USFDA). According to a notification issued by the agency, the batch was manufactured at DRL's Ltd, Bachupally unit and the recall was initiated under "Class II" classification. Rivastigmine Tartrate Capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type or Parkinson's disease. ALSO READ: Dr Reddy's looking at adding its might to start-ups in allied areas: G V Prasad According to the US health regulator, Class II recall is a situation in which the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Shares of Dr Reddy's traded at Rs 4,308 apiece, up 1.80 per cent over previous close on BSE .
Disqus for www.money99.in
Thursday, 20 August 2015
Dr Reddy's Laboratories has initiated voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market : 20 Aug 2015
Posted By:
Money99
- August 20, 2015
Subscribe to:
Post Comments (Atom)
Sponsor
Live Ami Charts
Demo chart
MCX Live chart
NSE Future Live chart
Nifty Option Live chart
FnO List of Equity Live chart
OTHER IMPORTANT LINKS
- SGX Nifty
- NSE StockFut. Live Chart
- MCX Live excel - Camarilla
- Ladder system for Crude oil
- Nifty 50 Live Excel Sheet
- Volatility tips
- Advanced Camarilla Live Excel
- Fibonacci Calculator
- Gold Price In India
- NSE FnO Lot Size
- Recent Dividends
- India Financial Data
- Commodity - 5 Basic tips
- Comex Future Price
- World Economic Calender
- Result Calendar
- NSE Bulk Deal
- FII & DII Activity
- ADV/DEC Sector Wise
- Forex Tools
- Advanced EOD chart
Alexa
Latest Post
Popular Posts
Labels
© Copyright 2015 Money99. Designed by Parag Patil
0 comentários:
Post a Comment